US approves first mRNA flu shot for seniors

The U.S. Food and Drug Administration (FDA) has approved the first flu vaccine based on mRNA technology. This development opens new options for seasonal flu vaccination for individuals over 50. The vaccine has received full approval for the age group of 50 to 64 years and has been granted emergency use authorization for those aged 65 and older, pending an additional study to assess its effectiveness in seniors. Trials have shown that the vaccine is approximately 27% more effective than traditional flu vaccines, and it is expected to be available in the coming weeks. The adoption of mRNA technology aims to develop flu vaccines more quickly and respond more effectively to changing seasonal strains, with potential temporary side effects such as injection site pain and fatigue.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل